84182-46-7

Basic information

• Product Name: 3-(BENZYLOXY)CYCLOBUTANE-1,1-DICARBOXYLIC ACID
• Synonyms: 3-(BENZYLOXY)CYCLOBUTANE-1,1-DICARBOXYLIC ACID;1,1-Cyclobutanedicarboxylic acid, 3-(phenylmethoxy)-
• CAS NO: 84182-46-7
• Molecular Formula: C₁₃H₁₄O₅
• Molecular Weight: 250.25
• Mol File: 84182-46-7.mol
• Article Data: 7

Chemical Properties

• Melting Point: ca 164℃
• Boiling Point: 465.7 °C at 760 mmHg
• Flash Point: 181 °C
• Appearance: /
• Density: 1.36 g/cm³
• Vapor Pressure: 1.8E-09mmHg at 25°C
• Refractive Index: 1.595
• CAS DataBase Reference: 3-(BENZYLOXY)CYCLOBUTANE-1,1-DICARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(BENZYLOXY)CYCLOBUTANE-1,1-DICARBOXYLIC ACID(84182-46-7)
• EPA Substance Registry System: 3-(BENZYLOXY)CYCLOBUTANE-1,1-DICARBOXYLIC ACID(84182-46-7)

Safety Data

• Statements: 36
• Safety Statements: 26
• HazardClass: IRRITANT
• Hazardous Substances Data: 84182-46-7(Hazardous Substances Data)

Usage

General Description

3-(Benzyloxy)cyclobutane-1,1-dicarboxylic acid is a chemical compound that belongs to the class of carboxylic acids. It is a cyclobutane derivative with two carboxylic acid groups and a benzyl ether functional group. 3-(BENZYLOXY)CYCLOBUTANE-1,1-DICARBOXYLIC ACID has potential applications in organic synthesis and pharmaceutical research. The presence of the benzyl ether group makes it a versatile building block for the synthesis of various heterocyclic compounds and biologically active molecules. Additionally, its cyclobutane core structure gives it unique reactivity and potential for use in the development of novel drug candidates. Overall, 3-(benzyloxy)cyclobutane-1,1-dicarboxylic acid is a valuable chemical for the advancement of organic and medicinal chemistry.

InChI:InChI=1/C13H14O5/c14-11(15)13(12(16)17)6-10(7-13)18-8-9-4-2-1-3-5-9/h1-5,10H,6-8H2,(H,14,15)(H,16,17)

Upstream product

• 100-39-0 benzyl bromide 
• 54307-67-4 1-bromo-2-benzyloxy-3-chloropropane 
• 54166-15-3 diethyl 3-(benzyloxy)cyclobutane-1,1-dicarboxylate 

Downstream Products

• 92146-77-5 3-amino-1-benzyloxycyclobutane 
• 154748-62-6 tert-butyl (3-(benzyloxy)cyclobutyl)carbamate 
• 1349184-62-8 N-((1S,3S)-3-(benzyloxy)cyclobutyl)benzo[d]thiazol-2-amine 
• 1349185-21-2 N-(2-aminophenyl)-3-(benzyloxy)cyclobutanecarboxamide 
• 1349185-23-4 2-(3-(benzyloxy)cyclobutyl)-1H-benzo[d]imidazole 
• 100390-24-7 3-benzyloxy-cyclobutanecarboxylic acid amide 
• 84182-59-2 hydrochloride of cis-3-aminocyclobutane-1-carboxylic acid 
• 74316-27-1 cis-3-aminocyclobutane-1-carboxylic acid 
• 74307-75-8 (1r,3r)-3-aminocyclobutane-1-carboxylic acid 
• 344338-13-2 methylester of 3-p-toluenesulfonyloxycyclobutane-1-carboxylic acid 
• 344348-50-1 amide of 3-p-toluenesulfonyloxycyclobutane-1-carboxylic acid 
• 4934-98-9 methylester of 3-benzyloxycyclobutane-1-carboxylic acid 

Relevant articles and documents

BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C

The disclosure provides compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS

The present invention relates to azetidine and cyclobutane derivatives, as well as their compositions, methods of use, and processes for preparation, which are JAK inhibitors useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

NEW PLEUROMUTILIN DERIVATIVE AND ITS USE

The invention is directed to the L-tartrate salt of trans-3-aminocyclobutyl (lS,2R,3S,4S:,6R,7R,8R-,14R)-4-ethenyl-3-hydroxy-2,4,7, 14-tetramethyl-9- oxotricyclo[5.4.3.01,8]tetradec-6-yl imidodicarbonate (Compound IA.) Compound IA is useful for the treatment of a variety of diseases and conditions, such as respiratory tract and skin and skin structure infections. Accordingly, the invention is further directed to pharmaceutical compositions comprising Compound IA. The invention is still further directed to methods of treating respiratory tract and skin and skin structure infections using Compound IA or a pharmaceutical composition comprising Compound IA.